Kerr Drug rolls out BloodSTOP
MOUNTAIN VIEW, Calif. Kerr Drug last week announced the introduction of a new bleeding control solution to its market with the introduction of BloodSTOP hemostatic gauze, manufactured by LifeScience PLUS.
“When I first saw BloodSTOP and the way it works, I was immediately interested,” stated Scott Porter, category manager – healthCare, Kerr Drug. “After sampling the product I was sold. BloodSTOP offers an exciting solution to a sleepy category. Kerr Drug is always looking for niche items that provide real and innovative solutions for our customers. I believe we hit a homerun here.”
Resembling a traditional bandage, BloodSTOP acts in less than a minute, reducing clotting times by as much as 75%. When applied to a wound, BloodSTOP quickly absorbs blood and other body fluids, transforms into a gel to seal the wound with a protective transparent layer, actively aids in blood coagulation, and creates an environment for wound healing. It is water soluble for easy removal without discomfort or disruption to the wound surface.
Diabetes population to double, costs to nearly triple by 2034
PRINCETON, N.J. The number of people in the United States with diabetes will nearly double over the next 25 years, while spending on the disease will nearly triple, according to a new report by researchers at the University of Chicago.
According to the study — commissioned by Danish drug maker Novo Nordisk through its National Changing Diabetes Program and published in the December issue of the journal Diabetes Care — 44.1 million people will have diabetes in 2034, while spending on the disease will total $336 billion. Those figures currently are 23.7 million and $113 billion, respectively. Meanwhile, Medicare patients with diabetes will more than double, from 6.5 million to 14.1 million, while Medicare spending will go from $45 billion this year to $171 billion in 2034.
“Obesity is a significant driver of future increases in the number of Americans with diabetes,” University of Chicago National Opinion Research Center researcher and study author Michael O’Grady said in a statement. “While our modeling, as well as that done by the Centers for Disease Control and Prevention, project obesity rates leveling off, neither model has obesity rates lowering substantially.”
The researchers used a model that considers factors not used by government budget analysts, including natural progression of the disease, effects of treatment and U.S. obesity rates.
“High obesity rates among the American population over an extended period of time substantially increases the probability of developing Type 2 diabetes,” O’Grady said.
CHPA elects new board members
WASHINGTON The Consumer Healthcare Products Association on Nov. 17 elected new board members and executive committee vice chairs, the association announced last week in its newsletter.
CHPA’s new board members include:
- William Hemelt, president and CEO, Matrixx Initiatives;
- Colleen Jay, VP North America personal health, global digestive wellness, Procter & Gamble;
- Matthew Mannelly, president and CEO, Prestige Brands;
- James Medford, president and CEO, Aaron Industries;
- Jeffrey Rowan, president and CEO, Fleet Laboratories; and
- Paul Sturman, president and GM, Pfizer Consumer Healthcare.
CHPA elected Charles Hough, OTC Business Unit, region head – North America, Novartis Consumer Health, Peter Luther, president, McNeil Consumer Healthcare; and Roger Scarlett-Smith, president, North America, Consumer Healthcare, GlaxoSmithKline as executive committee vice chairs.
In addition, CHPA’s board of directors elected four active member companies, including: Boiron, Essential Home OTCs, Heatmax and Honey Don’t Cough.